Lakewood-Amedex Biotherapeutics (LABT) Corporate presentation summary

Addressing antimicrobial resistance (AMR)

• AMR is a major global health threat, causing 1.14 million deaths annually and contributing to 4.7 million deaths worldwide, with significant economic impact projected by 2050.

• Systemic antibiotic overuse and agricultural practices drive resistance, while new antibiotics remain vulnerable and are reserved for severe cases.

Bisphosphocin® compounds and mechanism of action

• Bisphosphocin® is a novel class of small nucleotide derivatives targeting bacterial cell membranes, causing rapid cell death within minutes.

• Demonstrates broad-spectrum activity, including against resistant strains like MRSA and VRE, and is effective against biofilm organisms.

• Local delivery achieves high concentrations at infection sites, reducing systemic side effects and resistance risk.

Lead program: Nu-3 for infected diabetic foot ulcers (iDFU)

• Diabetic foot ulcers affect about one third of 830 million diabetics globally, with 50% becoming infected and high rates of recurrence and amputation.

• 15-20% of iDFUs involve resistant pathogens, primarily MRSA, and current treatments have poor outcomes.

• Nu-3 is a topically delivered gel with rapid, broad-spectrum, and cidal activity, showing robust efficacy in preclinical models and a strong safety profile.